We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top-Ranked ETFs in Focus on Rumored CVS-Aetna Deal
Read MoreHide Full Article
After a deluge of strong earnings reports from tech titans, the biggest story on Wall Street is the potential buyout of Aetna by CVS Health Corp (CVS - Free Report) . This is especially true, as a drug chain and a pharmacy giant CVS has proposed to acquire the nation's third-largest health insurer Aetna for more than $200 per share, or around $66 billion according to various sources.
This would represent the biggest deal of the year and the first tie-up of a retailer, an insurer and a pharmacy benefit manager in history. As such, the proposed deal would change the landscape of healthcare business as well as streamline and cut costs in the drug supply chain.
The merged company would create a one-stop shop for customers' health care needs, ranging from employer healthcare and government plans to managing benefits and running drug stores. By owning Aetna, CVS will become the first triple healthcare player: a drugstore, a pharmacy benefit manager and now an insurer. It would be in a better position to negotiate discounts with drug manufacturers. This is because CVS is one of the key players in the pharmacy benefit management business in the United States and often negotiates drug benefits for insurance plans and employers.
The move is also to stave off threats from Amazon.com Inc (AMZN - Free Report) , which is making huge expansion into the world of pharmaceutical drugs and has already received pharmacy-wholesaler licenses in a dozen states.
However, the transaction is expected to attract high antitrust scrutiny because of its sheer size and overlaps in Medicare Part D, a government program to subsidize prescription drug costs. Notably, CVS has a market capitalization of $77.76 billion while AET has a market cap of $53.35 billion. As such, the approval of the transaction might call for certain divestitures of Medicare prescription drug contracts.
ETF Impact
The proposed merger has put the spotlight on a few healthcare and consumer ETFs that could be the best ways for investors to tap the opportunity arising from the CVS-AET deal. These funds have a solid Zacks ETF Rank #2 (Buy), suggesting their outperformance in the coming months.
iShares U.S. Healthcare Providers ETF (IHF - Free Report)
This ETF follows the Dow Jones U.S. Select Healthcare Providers Index with exposure to companies that provide health insurance, diagnostics and specialized treatment. In total, the fund holds 45 securities in its basket with Aetna occupying the second position, accounting for 7.3% share. The fund has amassed $482.5 million in its asset base while volume is light at about 26,000 shares per day on average. It charges 44 bps in annual fees (see: all the Healthcare ETFs here).
The fund targets companies that have the potential to outperform the broad U.S. consumer staples sector and tracks the MSCI USA Consumer Staples Diversified Multiple-Factor Capped Index. Holding 28 stocks in its basket, CVS Health takes the fifth spot, accounting for 5.8% of the portfolio. In terms of industrial exposure, more than half of the portfolio is dominated by food beverage tobacco while food & staples retailing, and household and personal product take the remainder with a double-digit exposure each. This ETF has attracted $2.5 million in its asset base and trades in a meager volume of about 200 shares. It charges 35 bps in fees per year.
This fund provides exposure to the 26 largest retail firms by tracking the MVIS US Listed Retail 25 Index. Of these, CVS takes the sixth position with 5.04% share. The ETF has a certain tilt toward specialty retail, which accounts for 31% of the portfolio with 31%, while Internet direct marketing (22%), hypermarkets (12%), departmental stores (10%), and healthcare services (9%) round off the next four spots. The product has amassed $50.5 million in its asset base and charges 35 bps in annual fees. Volume is light as it exchanges more than 11,000 shares per day (read: Profit from Retailers' Defaults With These ETFs).
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top-Ranked ETFs in Focus on Rumored CVS-Aetna Deal
After a deluge of strong earnings reports from tech titans, the biggest story on Wall Street is the potential buyout of Aetna by CVS Health Corp (CVS - Free Report) . This is especially true, as a drug chain and a pharmacy giant CVS has proposed to acquire the nation's third-largest health insurer Aetna for more than $200 per share, or around $66 billion according to various sources.
This would represent the biggest deal of the year and the first tie-up of a retailer, an insurer and a pharmacy benefit manager in history. As such, the proposed deal would change the landscape of healthcare business as well as streamline and cut costs in the drug supply chain.
The merged company would create a one-stop shop for customers' health care needs, ranging from employer healthcare and government plans to managing benefits and running drug stores. By owning Aetna, CVS will become the first triple healthcare player: a drugstore, a pharmacy benefit manager and now an insurer. It would be in a better position to negotiate discounts with drug manufacturers. This is because CVS is one of the key players in the pharmacy benefit management business in the United States and often negotiates drug benefits for insurance plans and employers.
Additionally, the combined company could pose a bigger threat to UnitedHealth Group Inc. (UNH - Free Report) , the largest U.S. health insurer having its own pharmacy benefits unit (read: Ride On UnitedHealth Q3 Strength with These ETFs).
The move is also to stave off threats from Amazon.com Inc (AMZN - Free Report) , which is making huge expansion into the world of pharmaceutical drugs and has already received pharmacy-wholesaler licenses in a dozen states.
However, the transaction is expected to attract high antitrust scrutiny because of its sheer size and overlaps in Medicare Part D, a government program to subsidize prescription drug costs. Notably, CVS has a market capitalization of $77.76 billion while AET has a market cap of $53.35 billion. As such, the approval of the transaction might call for certain divestitures of Medicare prescription drug contracts.
ETF Impact
The proposed merger has put the spotlight on a few healthcare and consumer ETFs that could be the best ways for investors to tap the opportunity arising from the CVS-AET deal. These funds have a solid Zacks ETF Rank #2 (Buy), suggesting their outperformance in the coming months.
iShares U.S. Healthcare Providers ETF (IHF - Free Report)
This ETF follows the Dow Jones U.S. Select Healthcare Providers Index with exposure to companies that provide health insurance, diagnostics and specialized treatment. In total, the fund holds 45 securities in its basket with Aetna occupying the second position, accounting for 7.3% share. The fund has amassed $482.5 million in its asset base while volume is light at about 26,000 shares per day on average. It charges 44 bps in annual fees (see: all the Healthcare ETFs here).
iShares Edge MSCI Multifactor Consumer Staples ETF
The fund targets companies that have the potential to outperform the broad U.S. consumer staples sector and tracks the MSCI USA Consumer Staples Diversified Multiple-Factor Capped Index. Holding 28 stocks in its basket, CVS Health takes the fifth spot, accounting for 5.8% of the portfolio. In terms of industrial exposure, more than half of the portfolio is dominated by food beverage tobacco while food & staples retailing, and household and personal product take the remainder with a double-digit exposure each. This ETF has attracted $2.5 million in its asset base and trades in a meager volume of about 200 shares. It charges 35 bps in fees per year.
VanEck Vectors Retail ETF (RTH - Free Report)
This fund provides exposure to the 26 largest retail firms by tracking the MVIS US Listed Retail 25 Index. Of these, CVS takes the sixth position with 5.04% share. The ETF has a certain tilt toward specialty retail, which accounts for 31% of the portfolio with 31%, while Internet direct marketing (22%), hypermarkets (12%), departmental stores (10%), and healthcare services (9%) round off the next four spots. The product has amassed $50.5 million in its asset base and charges 35 bps in annual fees. Volume is light as it exchanges more than 11,000 shares per day (read: Profit from Retailers' Defaults With These ETFs).
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>